World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
51
Citations
10467
World Ranking
4139
National Ranking
1889

Hernan Valdez publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Hernan Valdez sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 172 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Hernan Valdez D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Hernan Valdez sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 51 D-Index — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Hernan Valdez is affiliated with Pfizer in the United States and has contributed extensively to the field of medicine, with a particular focus on dermatology and related subfields. Their research portfolio includes 136 publications in medicine, involving specialized areas such as dermatology, immunology and allergy, physiology, and rheumatology. Valdez's work encompasses a range of topics primarily centered on dermatology and skin diseases, allergic rhinitis and sensitization, asthma and respiratory diseases, pharmaceutical studies and practices, urticaria and related conditions, transgenic plants and applications, and food allergy and anaphylaxis research.

The scientist's research output includes numerous articles published in prominent journals. Their frequent publication venues include the Journal of the American Academy of Dermatology, American Journal of Clinical Dermatology, Journal of the European Academy of Dermatology and Venereology, Annals of Allergy Asthma & Immunology, and the Journal of Allergy and Clinical Immunology.

Among Hernan Valdez's notable recent papers are:

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial (2020, The Lancet)
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis (2021, New England Journal of Medicine)
  • Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis (2020, JAMA Dermatology)
  • Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data (2020, Annals of the Rheumatic Diseases)
  • Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial (2022, The Lancet)

Throughout their career, Valdez has frequently collaborated with other researchers, including Ricardo Rojo, Marco DiBonaventura, Jonathan I. Silverberg, Claire Feeney, and Eric L. Simpson. These partnerships have contributed to a body of work with a strong interdisciplinary approach, particularly focused on dermatology and immunological conditions.

Best Publications

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

    Eric L Simpson;Rodney Sinclair;Seth Forman;Andreas Wollenberg

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

    Thomas Bieber;Eric L. Simpson;Jonathan I. Silverberg;Diamant Thaçi

  • Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

    Unknown

  • Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

    Jonathan I. Silverberg;Eric L. Simpson;Jacob P. Thyssen;Melinda J. Gooderham

  • Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

    Peter W. Hunt;Steven G. Deeks;Benigno Rodriguez;Hernan Valdez

  • Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function

    Luciléia Teixeira;Hernan Valdez;Joseph M. McCune;Richard A. Koup

  • Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.

    Hernan Valdez;Elizabeth Connick;Elizabeth Connick;Kimberly Y. Smith;Kimberly Y. Smith;Michael M. Lederman

  • Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

    Kevin L. Winthrop;S. H. Park;A. Gul;M. H. Cardiel

  • Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

    Unknown

  • Thymic Size and Lymphocyte Restoration in Patients with Human Immunodeficiency Virus Infection after 48 Weeks of Zidovudine, Lamivudine, and Ritonavir Therapy

    Kimberly Y. Smith;H. Valdez;A. Landay;J. Spritzler

  • Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection

    Christoph G Lange;Michael M Lederman;Kathy Medvik;Robert Asaad

  • Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic.

    Dong Zhang;Premlata Shankar;Premlata Shankar;Zhan Xu;Zhan Xu;Brooke Harnisch;Brooke Harnisch

  • Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection.

    Donald D Anthony;Nicole L. Yonkers;Anthony B Post;Robert Asaad

  • CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection.

    Gang Chen;Premlata Shankar;Christoph Lange;Hernan Valdez

  • Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen

    Hernan Valdez;Kimberly Y. Smith;Alan Landay;Elizabeth Connick

  • Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

    Raymond T. Chung;Scott R. Evans;Yijun Yang;Dickens Theodore

  • Immune restoration with antiretroviral therapies: implications for clinical management.

    Michael Marcel Lederman;Hernan Valdez

  • Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.

    Philip Mease;Christina Charles-Schoeman;Stanley Cohen;Lara Fallon

  • Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths during 1995–1999

    Hernan Valdez;Tanvir K. Chowdhry;Robert Asaad;Ian J. Woolley

  • Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients

    Luke C. Swenson;Theresa Mo;Winnie W.Y. Dong;Xiaoyin Zhong

  • Population-based V3 Genotypic Tropism Assay: A Retrospective Analysis Using Screening Samples From the A4001029 and MOTIVATE Studies

    Rachel A McGovern;Alexander Thielen;Theresa Mo;Winnie Dong

  • Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

    Mary A. Albrecht;Ronald J. Bosch;Scott M. Hammer;Song-Heng Liou

  • Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.

    R Bissonnette;Lars Iversen;H Sofen;C E M Griffiths

  • Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study

    James Krueger;James D. Clark;Mayte Suárez-Fariñas;Judilyn Fuentes-Duculan

  • Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.

    Lawrence F Eichenfield;Carsten Flohr;Robert Sidbury;Elaine Siegfried

  • Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.

    Andrew Blauvelt;Jonathan I. Silverberg;Charles W. Lynde;Thomas Bieber

Frequent Co-Authors

Michael M. Lederman
Michael M. Lederman Case Western Reserve University
Alan L. Landay
Alan L. Landay The University of Texas Medical Branch at Galveston
Daniel R. Kuritzkes
Daniel R. Kuritzkes Brigham and Women's Hospital
Christoph Lange
Christoph Lange University of Lübeck
Benigno Rodriguez
Benigno Rodriguez Case Western Reserve University
Harold A. Kessler
Harold A. Kessler Rush University Medical Center
Robert A. Salata
Robert A. Salata Case Western Reserve University
Grace A. McComsey
Grace A. McComsey Case Western Reserve University
Richard B. Pollard
Richard B. Pollard University of California, Davis
David Katzenstein
David Katzenstein Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, exploring related healthcare fields through online degrees can expand career opportunities. Many students pursue programs that complement their understanding of the immune system, such as nursing specializations. Finding the cheapest online pmhnp programs can make advanced practice nursing more accessible without sacrificing quality education.

Career advancement often involves certification and specialization. For example, nurses might look into acute care nurse practitioner certification to move from family nursing to acute care settings that require in-depth clinical expertise, often related to immunological conditions.

Accelerated pathways are available for working registered nurses who want to become nurse practitioners quickly. These are detailed in the accelerated rn to np programs, offering flexible options for career growth while balancing professional and personal commitments.

Understanding salary dynamics is also important. According to data on how much do dnps make, earnings vary by location and specialty, with advanced degrees like a Doctor of Nursing Practice often leading to higher compensation. This financial insight helps students make informed decisions about their education and career path.

Best Scientists Citing Hernan Valdez

Trending Scientists

Recently Published Articles